Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma

被引：0
|
作者：
Brigitte Dréno
Paolo A Ascierto
Victoria Atkinson
Gabriella Liszkay
Michele Maio
Mario Mandalà
Lev Demidov
Daniil Stroyakovskiy
Luc Thomas
Luis de la Cruz-Merino
Caroline Dutriaux
Claus Garbe
Karen Bartley
Thomas Karagiannis
Ilsung Chang
Isabelle Rooney
Daniel O Koralek
James Larkin
Grant A McArthur
Antoni Ribas
机构：
[1] Nantes University,Department of Dermato Cancerology
[2] Istituto Nazionale Tumori Fondazione G. Pascale,Department of Oncology and Haematology
[3] Princess Alexandra Hospital,Department of Dermatology
[4] National Institute of Oncology,undefined
[5] Azienda Ospedaliera Universitaria Senese,undefined
[6] Papa Giovanni XXIII Hospital,undefined
[7] N. N. Blokhin Russian Cancer Research Center,undefined
[8] Moscow City Oncology Hospital 62,undefined
[9] Service de Dermatologie,undefined
[10] Centre Hospitalier Lyon Sud,undefined
[11] Hospital Universitario Virgen Macarena,undefined
[12] Hôpital Saint André,undefined
[13] University of Tübingen,undefined
[14] Genentech,undefined
[15] Inc.,undefined
[16] The Royal Marsden NHS Foundation Trust,undefined
[17] Peter MacCallum Cancer Centre,undefined
[18] East Melbourne,undefined
[19] VIC 3002,undefined
[20] Australia,undefined
[21] University of Melbourne,undefined
[22] Jonsson Comprehensive Cancer Center,undefined
[23] University of California Los Angeles,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
vemurafenib; cobimetinib; MEK inhibitor; BRAF inhibitor; HRQOL; EORTC QLQ-C30; metastatic melanoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：777 / 784
页数：7
相关论文
共 50 条
  • [1] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
    Dreno, Brigitte
    Ascierto, Paolo A.
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Bartley, Karen
    Karagiannis, Thomas
    Chang, Ilsung
    Rooney, Isabelle
    Koralek, Daniel O.
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 777 - 784
  • [2] Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (05) : 605 - 615
  • [3] Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma
    Gillian M. Keating
    Drugs, 2016, 76 : 605 - 615
  • [4] Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib
    Schadendorf, Dirk
    Di Giacomo, Anna Maria
    Demidov, Lev
    Merelli, Barbara
    Bondarenko, Igor
    Ascierto, Paolo A.
    Herbert, Christopher
    Mackiewicz, Andrzej
    Rutkowski, Piotr
    Guminski, Alexander
    Goodman, Grant R.
    Simmons, Brian
    Ye, Chenglin
    Hong, Agnes
    Lewis, Karl
    EUROPEAN JOURNAL OF CANCER, 2019, 123 : 155 - 161
  • [5] BRAFV600 mutation levels and response to vemurafenib in metastatic melanoma.
    Lebbe, Celeste
    Howkit, Alexandre
    Sadoux, Aurelie
    Podgorniak, Marie Pierre
    Battistella, Maxime
    Pages, Cecile
    Roux, Jennifer
    Porcher, Raphael
    Tost, Jorg
    Mourah, Samia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, C.
    How-Kit, A.
    Battistella, M.
    Sadoux, A.
    Podgorniak, M. P.
    Sidina, I.
    Pages, C.
    Roux, J.
    Porcher, R.
    Tost, J.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 96 - 96
  • [7] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, Celeste
    How-Kit, Alexandre
    Battistella, Maxime
    Sadoux, Aurelie
    Podgorniak, Marie-Pierre
    Sidina, Irina
    Pages, Cecile
    Roux, Jennifer
    Porcher, Raphael
    Tost, Jorg
    Mourah, Samia
    MELANOMA RESEARCH, 2014, 24 (04) : 415 - 418
  • [8] Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma
    Robert, C.
    Lewis, K. D.
    Gutzmer, R.
    Stroyakovskiy, D.
    Gogas, H.
    Protsenko, S.
    Pereira, R. P.
    Eigentler, T.
    Rutkowski, P.
    Demidov, L.
    Caro, I
    Forbes, H.
    Shah, K.
    Yan, Y.
    Li, H.
    McArthur, G. A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 544 - 555
  • [9] Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
    Lewis, Karl
    Hauschild, Axel
    Larkin, James
    Ribas, Antoni
    Flaherty, Keith T.
    McArthur, Grant A.
    Dreno, Brigitte
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Ascierto, Paolo A.
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 45 - 55
  • [10] CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma
    Lesimple, T.
    Campillo-Gimenez, B.
    Leccia, M. T.
    Mahmoudi, A.
    Lebbe, C.
    MELANOMA RESEARCH, 2016, 26 : E47 - E48
12345